Evidence map›Paper›PMID 28025562›Full record

ArticleInternational journal of molecular sciences2016

Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells.

Rosaliana Libro, Francesca Diomede, Domenico Scionti, Adriano Piattelli, Gianpaolo Grassi, Federica Pollastro, Placido Bramanti, Emanuela Mazzon, Oriana Trubiani

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Cannabinoids for the treatment of dementia.The Cochrane database of systematic reviews · 2021
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. The Use of Compounds Derived fromInternational journal of molecular sciences · 2024
    Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Rosaliana LibroIRCCS Centro Neurolesi "Bonino-Pulejo", via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy. rosalianalibro@hotmail.it.
Francesca DiomedeStem Cells and Regenerative Medicine Laboratory, Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio", Chieti-Pescara, via dei Vestini, 31, 66100 Chieti, Italy. francesca.diomede@unich.it.
Domenico SciontiIRCCS Centro Neurolesi "Bonino-Pulejo", via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy. domenico.scionti@gmail.com.
Adriano PiattelliStem Cells and Regenerative Medicine Laboratory, Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio", Chieti-Pescara, via dei Vestini, 31, 66100 Chieti, Italy. adriano.piattelli@unich.it.
Gianpaolo GrassiCouncil for Research and Experimentation in Agriculture-Research Centre for Industrial Crops (CREA-CIN), 45100 Rovigo, Italy. giampaolo.grassi@gmail.com.
Federica PollastroDipartimento di Scienze del Farmaco, Universita del Piemonte Orientale, Largo Donegani 2, 28100 Novara, Italy. federica.pollastro@uniupo.it.
Placido BramantiIRCCS Centro Neurolesi "Bonino-Pulejo", via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy. bramanti.dino@gmail.com.
Emanuela MazzonIRCCS Centro Neurolesi "Bonino-Pulejo", via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy. emazzon.irccs@gmail.com.
Oriana TrubianiStem Cells and Regenerative Medicine Laboratory, Department of Medical, Oral and Biotechnological Sciences, University "G. D'Annunzio", Chieti-Pescara, via dei Vestini, 31, 66100 Chieti, Italy. trubiani@unich.it.
Centro Neurolesi Bonino Pulejo · ITUniversity of Chieti-Pescara · ITResearch Centre for Cereal and Industrial Crops · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem cells (MSCs) have emerged as a promising tool for the treatment of several neurodegenerative disorders, including Alzheimer's disease (AD). The main neuropathological hallmarks of AD are senile plaques, composed of amyloid beta (Aβ), and neurofibrillary tangles, formed by hyperphosphorylated tau. However, current therapies for AD have shown limited efficacy. In this study, we evaluated whether pre-treatment with cannabidiol (CBD), at 5 μM concentration, modulated the transcriptional profile of MSCs derived from gingiva (GMSCs) in order to improve their therapeutic potential, by performing a transcriptomic analysis by the next-generation sequencing (NGS) platform. By comparing the expression profiles between GMSCs treated with CBD (CBD-GMSCs) and control GMSCs (CTR-GMSCs), we found that CBD led to the downregulation of genes linked to AD, including genes coding for the kinases responsible of tau phosphorylation and for the secretases involved in Aβ generation. In parallel, immunocytochemistry analysis has shown that CBD inhibited the expression of GSK3β, a central player in AD pathogenesis, by promoting PI3K/Akt signalling. In order to understand through which receptor CBD exerted these effects, we have performed pre-treatments with receptor antagonists for the cannabinoid receptors (SR141716A and AM630) or for the vanilloid receptor 1 (TRPVI). Here, we have proved that TRPV1 was able to mediate the modulatory effect of CBD on the PI3K/Akt/GSK3β axis. In conclusion, we have found that pre-treatment with CBD prevented the expression of proteins potentially involved in tau phosphorylation and Aβ production in GMSCs. Therefore, we suggested that GMSCs preconditioned with CBD possess a molecular profile that might be more beneficial for the treatment of AD.

Indexed as

TranscriptomeAlzheimer DiseaseAmyloid beta-PeptidesCannabidiolCells, CulturedGlycogen Synthase Kinase 3 betaHumansMaleMesenchymal Stem CellsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akttau ProteinsTRPV Cation ChannelsAmyloid beta-PeptidesCannabidiolGlycogen Synthase Kinase 3 betaPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akttau ProteinsTRPV1 protein, humanTRPV Cation ChannelsAlzheimer’s diseaseamyloid betacannabidiolglycogen synthase kinase 3βmesenchymal stem cellstau

Identifiers

PMID28025562
PMCPMC5297661
OpenAlexW2565474450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.